Neurocrine Biosciences Trading Near Its 52-Week Low As Delta Threatens The Ingrezza Rebound
koto_feja/E+ via Getty Images
This has been a lousy stretch for Neurocrine Biosciences (NBIX), and just as the company showed a much-needed better-than-expected quarterly result for lead drug Ingrezza, the surge in COVID-19 infections tied to the delta…
